Abstract
Since the first case of priapism was reported in the scientific literature in 1824, limited attention has been placed on the study of the incidence, etiology, pathophysiology, diagnosis, and timely treatment of priapism. As a result priapism is associated with less than ideal patient outcomes including permanent and irreversible erectile dysfunction, and the concomitant devastating psychosocial consequences. Well-designed, community-based epidemiologic studies investigating the prevalence and incidence of priapism are limited. Current data reveal that the incidence of priapism in the general population is low (0.3–1.1 cases per 100,000 person–years). However, the prevalence of priapism in countries with the higher incidence of hemoglobinopathies, such as sickle cell disease, is much higher. The etiology of priapism is complex, but drugs are responsible for up to 80 % of cases. The most important predictive value in the maintenance of premorbid erectile function is duration of priapism, which makes rapid intervention essential. Guidelines and recommendations from the American Urological Association are critical in the management of patients with priapism.KeywordsSickle Cell DiseaseFabry DiseasePhosphodiesterase TypePerineal TraumaSympathomimetic AgentThese keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call